Belgium· BE-AMP-SAM515244-00
Synagis 100 mg/ml
A palivizumab product containing palivizumab, registered in Belgium by AstraZeneca. The same ATC class is registered in 13 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Palivizumab is registered in 13 of 19 countries.
Countries holding a registration under ATC J06BD01 (palivizumab), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 9 of them publish a price we can compare per daily dose
Palivizumab · ATC J06BD01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of palivizumab costs, country by country.
Normalised to the WHO defined daily dose (3.75 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Palivizumab · price per daily dose (3.75 mg)
USD · FX 28 Sept 2026
- CH Switzerland$51.40
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Palivizumab
- Manufacturer
- AstraZeneca
- Country
- Belgium (BE)
- ATC code
- J06BD01
- ATC class
- Palivizumab
- Defined daily dose
- 3.75 mg, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb7718166
- be_apb3456753
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Palivizumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NorwaySynagisAstraZeneca
- SwitzerlandSynagis 100 mg/1 ml, InjektionslösungAstraZeneca AG
- CzechiaSYNAGISAstraZeneca AB, Södertälje
- SpainSYNAGIS 100 mg/1 ml SOLUCION INYECTABLEAstrazeneca Ab
- SwedenSynagis 100 mg/1 ml Injektionsvätska, lösningAstraZeneca AB
- IcelandSynagisAstraZeneca AB*
- PolandSynagisAstraZeneca AB
- FinlandSynagisAstraZeneca AB
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Synagis
- Liechtenstein · Synagis
- Norway · Synagis
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/505efc7b-81d2-4794-be7a-ccb8096fc6a3 GET /v1/drugs/505efc7b-81d2-4794-be7a-ccb8096fc6a3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Synagis 100 mg/ml",
"name_fr": "Synagis 100 mg/ml",
"name_nl": "Synagis 100 mg/ml",
"amp_code": "SAM515244-00",
"strengths": [
"100.0000"
],
"pack_count": 1,
"substances": [
"Palivizumab"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Palivizumab",
"authorisation_numbers": [
"EU/1/99/117/003"
]
}See everything about palivizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.